In 2017, diabetes continued to pull in the profits for the key players in the metabolic disorders market, representing 66% of total metabolic sales.
The top five companies in the metabolic space mainly attribute their success to the sales of their anti-diabetic drugs. This is unsurprising as the number of US patients diagnosed with diabetes breached 32 million in 2017.
Go deeper with GlobalData
Novo Nordisk is currently the world leader in the diabetes market and will remain so for years to come. The company boasted sales of $13.7 million in 2017. Sanofi/Regeneron and Amgen will further strengthen their position in the metabolic disorders space with their expected blockbusters Praluent and Repatha, despite initial slow uptake in 2017.
Currently, 15 out of 20 top-selling drugs in the metabolic disorders space are anti-diabetics. With Sanofi’s Lantus and Merck & Co’s Januvia generating the most in sales in 2017, $5.1 and $3.7 billion, respectively. The majority of these top-selling anti-diabetics have already reached the peak of their sales, however, and are unlikely to continue to drive growth in the market. Instead, currently marketed drugs, Trulicity, Tresiba, Praluent, and Repatha are most likely to drive the growth of the metabolic disorders market in coming years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
